Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Aronne LJ, Sattar N, Horn DB, et al. JAMA 2024;331:38-48.
What it found
After a mean 20.9% loss in the lead-in, those who continued tirzepatide lost a further 5.5% while those switched to placebo regained 14.0%. 89.5% on tirzepatide vs 16.6% on placebo kept at least 80% of their earlier weight loss.
Limitations
Only people who tolerated the drug and completed the lead-in were randomised. Adults without diabetes.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.